Transcriptional suppression of CYP2A13 expression by lipopolysaccharide in cultured human lung cells and the lungs of a CYP2A13-humanized mouse model

Toxicological Sciences

Volumn 135, Issue 2, 2013, Pages 476-485

  Wu, Hong ^a,b   Liu, Zhihua ^a,b   Ling, Guoyu ^a,b   Lawrence, David ^a,b   Ding, Xinxin ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Chemical carcinogenesis.; CYP2A; Inflammation; LPS; Lung

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOCHROME P450; CYTOCHROME P450 2A13; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; NITROSAMINE; NUCLEAR PROTEIN; PYRROLIDINE DITHIOCARBAMATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYP2A13 GENE; DOWN REGULATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; LUNG TOXICITY; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; TOBACCO; TRANSCRIPTION TERMINATION;

CHEMICAL CARCINOGENESIS.; CYP2A; INFLAMMATION; LPS; LUNG;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; HUMANS; LIPOPOLYSACCHARIDES; MICE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84886561969     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft165     Document Type: Article

References (44)

1. Abdulla, D., Goralski, K. B., Del Busto Cano, E. G., and Renton, K. W. (2005). The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation. Drug Metab. Dispos. 33, 1521-1531.
2. Aitken, A. E., Richardson, T. A., and Morgan, E. T. (2006). Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46, 123-149.
3. Akira, S., Taga, T., and Kishimoto, T. (1993). Interleukin-6 in biology and medicine. Adv. Immunol. 54, 1-78.
4. Akiyama, T. E., and Gonzalez, F. J. (2003). Regulation of P450 genes by liverenriched transcription factors and nuclear receptors. Biochim. Biophys. Acta 1619, 223-234.
5. Charles, K. A., Rivory, L. P., Brown, S. L., Liddle, C., Clarke, S. J., and Robertson, G. R. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res. 12, 7492-7497.
6. Corteling, R., Wyss, D., and Trifilieff, A. (2002). In vivo models of lung neutrophil activation. Comparison of mice and hamsters. BMC Pharmacol. 2, 1.
7. D'Agostino, J., Zhang, X., Wu, H., Ling, G., Wang, S., Zhang, Q. Y., Liu, F., and Ding, X. (2008). Characterization of CYP2A13.*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metab. Dispos. 36, 2316-2323.
8. D'Agostino, J., Zhuo, X., Shadid, M., Morgan, D. G., Zhang, X., Humphreys, W. G., Shu, Y. Z., Yost, G. S., and Ding, X. (2009). The pneumotoxin 3-methylindole is a substrate and a mechanism-based inactivator of CYP2A13, a human cytochrome P450 enzyme preferentially expressed in the respiratory tract. Drug Metab. Dispos. 37, 2018-2027.
9. Didon, L., Qvarfordt, I., Andersson, O., Nord, M., and Riise, G. C. (2005). Decreased CCAAT/enhancer binding protein transcription factor activity in chronic bronchitis and COPD. Chest 127, 1341-1346.
10. Ding, X., and Coon, M. J. (1990). Immunochemical characterization of multiple forms of cytochrome P-450 in rabbit nasal microsomes and evidence for tissue-specific expression of P-450s NMa and NMb. Mol. Pharmacol. 37, 489-496.
11. Duan, Q., Wang, X., Gong, W., Ni, L., Chen, C., He, X., Chen, F., Yang, L., Wang, P., and Wang, D. W. (2012). ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One 7, e31518.
12. Eggesbo, J. B., Hjermann, I., Lund, P. K., Joø, G. B., Ovstebø, R., and Kierulf, P. (1994). LPS-induced release of IL-1 beta, IL-6, IL-8, TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine 6, 521-529.
13. Getchell, M. L., Chen, Y., Ding, X., Sparks, D. L., and Getchell, T. V. (1993). Immunohistochemical localization of a cytochrome P-450 isozyme in human nasal mucosa: Age-related trends. Ann. Otol. Rhinol. Laryngol. 102, 368-374.
14. Gilmore, W. J., Hartmann, G., Piquette-Miller, M., Marriott, J., and Kirby, G. M. (2003). Effects of lipopolysaccharide-stimulated inflammation and pyrazole- mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. Toxicology 184, 211-226.
15. Gu, J., Zhang, Q. Y., Genter, M. B., Lipinskas, T. W., Negishi, M., Nebert, D. W., and Ding, X. (1998). Purification and characterization of heterologously expressed mouse CYP2A5 and CYP2G1: Role in metabolic activation of acetaminophen and 2,6-dichlorobenzonitrile in mouse olfactory mucosal microsomes. J. Pharmacol. Exp. Ther. 285, 1287-1295.
16. Halsey, T. A., Yang, L., Walker, J. R., Hogenesch, J. B., and Thomas, R. S. (2007). A functional map of NFkappaB signaling identifies novel modulators and multiple system controls. Genome Biol. 8, R104.
17. He, X. Y., Shen, J., Ding, X., Lu, A. Y., and Hong, J. Y. (2004). Identification of critical amino acid residues of human CYP2A13 for the metabolic activationof 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab. Dispos. 32, 1516-1521.
18. He, X. Y., Tang, L., Wang, S. L., Cai, Q. S., Wang, J. S., and Hong, J. Y. (2006). Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int. J. Cancer 118, 2665-2671.
19. Iber, H., Chen, Q., Cheng, P. Y., and Morgan, E. T. (2000). Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch. Biochem. Biophys. 377, 187-194.
20. Isajevs, S., Taivans, I., Svirina, D., Strazda, G., and Kopeika, U. (2011). Patterns of inflammatory responses in large and small airways in smokers with and without chronic obstructive pulmonary disease. Respiration. 81, 362-371.
21. Jalas, J. R., Hecht, S. S., and Murphy, S. E. (2005). Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol. 18, 95-110.
22. Jiang, J. G., and Zarnegar, R. (1997). A novel transcriptional regulatory region within the core promoter of the hepatocyte growth factor gene is responsible for its inducibility by cytokines via the C/EBP family of transcription factors. Mol. Cell. Biol. 17, 5758-5770.
23. Ke, S., Rabson, A. B., Germino, J. F., Gallo, M. A., and Tian, Y. (2001). Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factoralpha and lipopolysaccharide. J. Biol. Chem. 276, 39638-39644.
24. Koskela, S., Hakkola, J., Hukkanen, J., Pelkonen, O., Sorri, M., Saranen, A., Anttila, S., Fernandez-Salguero, P., Gonzalez, F., and Raunio, H. (1999). Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57, 1407-1413.
25. Ling, G., Wei, Y., and Ding, X. (2007). Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation. Mol. Pharmacol. 71, 807-816.
26. Megaraj, V., Zhou, X., Xie, F., Liu, Z., Yang, W., and Ding, X. (2013) Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): in vivo studies using a CYP2A13-humanized mouse model. Carcinogenesis. doi:10.1093/carcin/bgt269
27. Miyazawa, K., Mori, A., Yamamoto, K., and Okudaira, H. (1998). Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappaB, and C-promoter binding factor 1 in interleukin (IL)-1betainduced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J. Biol. Chem. 273, 7620-7627.
28. Morgan, E. T. (2001). Regulation of cytochrome p450 by inflammatory mediators: Why and how? Drug Metab. Dispos. 29, 207-212.
29. Nakajima, M., Itoh, M., Sakai, H., Fukami, T., Katoh, M., Yamazaki, H., Kadlubar, F. F., Imaoka, S., Funae, Y., and Yokoi, T. (2006). CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int. J. Cancer 119, 2520-2526.
30. Richardson, T. A., and Morgan, E. T. (2005). Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J. Pharmacol. Exp. Ther. 314, 703-709.
31. Stein, B., Cogswell, P. C., and Baldwin, A. S., Jr. (1993). Functional and physical associations between NF-kappa B and C/EBP family members: A Rel domain-bZIP interaction. Mol. Cell. Biol. 13, 3964-3974.
32. Stoilov, I., Krueger, W., Mankowski, D., Guernsey, L., Kaur, A., Glynn, J., and Thrall, R. S. (2006). The cytochromes P450 (CYP) response to allergic inflammation of the lung. Arch. Biochem. Biophys. 456, 30-38.
33. Su, T., Bao, Z., Zhang, Q. Y., Smith, T. J., Hong, J. Y., and Ding, X. (2000). Human cytochrome P450 CYP2A13: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 60, 5074-5079.
34. Sunman, J. A., Hawke, R. L., LeCluyse, E. L., and Kashuba, A. D. (2004). Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab. Dispos. 32, 359-363.
35. Tilstra, J. S., Clauson, C. L., Niedernhofer, L. J., and Robbins, P. D. (2011). NF-?B in aging and disease. Aging Dis. 2, 449-465.
36. Wang, H., Tan, W., Hao, B., Miao, X., Zhou, G., He, F., and Lin, D. (2003). Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. 63, 8057-8061.
37. Wei, Y., Wu, H., Li, L., Liu, Z., Zhou, X., Zhang, Q. Y., Weng, Y., D'Agostino, J., Ling, G., Zhang, X., et al. (2012). Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model. Drug Metab. Dispos. 40, 1144-1150.
38. Wu, H., Zhang, X., Ling, G., D'Agostino, J., and Ding, X. (2009). Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: Allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cisregulatory single nucleotide polymorphisms. Pharmacogenet. Genomics 19, 852-863.
39. Yanagihara, K., Seki, M., and Cheng, P. W. (2001). Lipopolysaccharide induces mucus cell metaplasia in mouse lung. Am. J. Respir. Cell Mol. Biol. 24, 66-73.
40. Zemke, A. C., Snyder, J. C., Brockway, B. L., Drake, J. A., Reynolds, S. D., Kaminski, N., and Stripp, B. R. (2009). Molecular staging of epithelial maturation using secretory cell-specific genes as markers. Am. J. Respir. Cell Mol. Biol. 40, 340-348.
41. Zhang, X., Caggana, M., Cutler, T. L., and Ding, X. (2004). Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung. J. Pharmacol. Exp. Ther. 311, 373-381.
42. Zhang, X., D'Agostino, J., Wu, H., Zhang, Q. Y., von Weymarn, L., Murphy, S. E., and Ding, X. (2007). CYP2A13: Variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 323, 570-578.
43. Zhou, X., Zhuo, X., Xie, F., Kluetzman, K., Shu, Y. Z., Humphreys, W. G., and Ding, X. (2010). Role of CYP2A5 in the clearance of nicotine and cotinine: Insights from studies on a Cyp2a5-null mouse model. J. Pharmacol. Exp. Ther. 332, 578-587.
44. Zhu, L. R., Thomas, P. E., Lu, G., Reuhl, K. R., Yang, G. Y., Wang, L. D., Wang, S. L., Yang, C. S., He, X. Y., and Hong, J. Y. (2006). CYP2A13 in human respiratory tissues and lung cancers: An immunohistochemical study with a new peptide-specific antibody. Drug Metab. Dispos. 34, 1672-1676.